Observational Study
Copyright ©The Author(s) 2019.
World J Gastrointest Oncol. Oct 15, 2019; 11(10): 887-897
Published online Oct 15, 2019. doi: 10.4251/wjgo.v11.i10.887
Table 3 Profiles of acylcarnitine in non-steatohepatitis patients without and with hepatocellular carcinoma
VariablePatients without HCC (n = 19)Patients with HCC (n = 14)P value
Acetylcarnitine (AC2)3.96 (3.33–4.92)2.06 (1.335–2.255)< 0.05
Propionylcarnitine (AC3)0.339 (0.2875–0.4115)0.3375 (< 0.24–0.473)NS
Butyrylcarnitine (AC4)< 0.1 (< 0.1–0.1)0.0795 (< 0.1–0.196)NS
Isovalerylcarnitine (AC5)< 0.06 (< 0.06–0.1085)< 0.06 (< 0.06–0.0787)NS
Glutarylcarnitine (AC5DC)< 0.05 (< 0.05–0.05)< 0.05 (< 0.05–0.05)NS
3-hydroxy isovalerylcarnitine (AC5OH)< 0.1 (< 0.1–0.1)< 0.1 (< 0.1–0.1)NS
Hexanoylcarnitine (AC6)0.0531 (< 0.05–0.0596)< 0.05 (< 0.05–0.05)< 0.05
Octanoylcarnitine (AC8)0.176 (0.1425–0.2375)0.0871 (0.0622–0.11025)< 0.05
Decanoylcarnitine (AC10)0.335 (0.256–0.432)0.1315 (0.099675–0.171)< 0.05
Dodecanolycarnitine (AC12)0.105 (0.0849–0.1335)0.02725 (0–0.06195)< 0.05
Myristoylcarnitine (AC14)< 0.06 (< 0.06–0.06)< 0.06 (< 0.06–0.06)NS
Myristoleylcarnitine (AC14:1)0.185 (0.134–0.2325)0.07825 (0.06305–0.09855)< 0.05
Palmitoylcarnitine (AC16)0.133 (0.1255–0.1485)0.116 (0.10425–0.1310)NS
3-hydroxy palmitoylcarnitine (AC16OH)< 0.03 (< 0.03–0.03)< 0.03 (< 0.0 –0.03)NS
Octadecanoylcarnitine (AC18)0.0429 (0.03245–0.04775)0.03315 (0.006625–0.039525< 0.05
Oleoylcarnitine (AC18:1)0.871 (0.6825–1.0350)0.721 (0.61275–0.83775)NS
3-hydroxy octadecenoylcarnitine (AC18:1OH)< 0.025 (< 0.025–0.02615)< 0.025 (< 0.025–0.025)NS
Short-chain fatty acids (AC2–AC6)4.3362 (3.83995–5.561750)2.4316 (1.86085–2.994125)< 0.05
Medium-chain fatty acids (AC8 + AC10)0.50600 (0.40700–0.69100)0.21385 (0.16545–0.28075)< 0.05
Long-chain fatty acid (AC12–AC18:1OH)1.3668 (1.106550–1.5871)0.9425 (0.836625–1.1087)< 0.05